The adenomatous polyposis coli (Apc) gene is mutated in up to 80% of sporadic colorectal cancers and is thought to be the key initiating event (Kinzler et al., 1991; Bienz and Clevers, 2000) . The predominant role of Apc gene as a tumour suppressor is as a negative regulator of the Wnt signalling pathway. APC forms part of the b-catenin destruction complex, along with glycogen synthase kinase-3 (GSK3), axin and casein kinase 1 (Bienz and Clevers, 2000) . This complex allows the phosphorylation of b-catenin by GSK3, which targets b-catenin for degradation by the proteasome. In the absence of APC (or in the presence of Wnt signal), this destruction complex is dissociated and b-catenin accumulates and translocates into the nucleus, where it interacts with TCF/LEF transcription factors to drive transcription of TCF/LEF (or Wnt) target genes (Korinek et al., 1997) .
Given the central nature of APC loss to colorectal cancer, we and others have previously investigated the phenotypes of APC loss within the murine intestinal epithelium and the associated Wnt target gene signature (Sansom et al., 2004; Andreu et al., 2005; Gregorieff and Clevers, 2005) . These studies have shown that conditional deletion of Apc within the intestinal epithelium (using cre-lox technology) leads to a 'crypt progenitor cell-like' phenotype, with intestinal enterocytes showing hyperproliferation, perturbed differentiation and migration (Sansom et al., 2004; Andreu et al., 2005) . Mechanistically, this phenotype is associated with concurrent nuclear b-catenin and transcriptional activation of a large number of Wnt target genes. Of these target genes, the proto-oncogene Myc (He et al., 1998) appears to be of central importance, as co-deletion of both Apc and Myc within the murine intestinal epithelium rescues this 'crypt progenitor cell-like' phenotype. Concordantly, many of the Wnt targets deregulated after APC loss revert back to wild-type levels in double knockout APC Myc intestinal enterocytes (Ignatenko et al., 2006; Sansom et al., 2007) .
One of the potential caveats to this study is that c-Myc was completely ablated and given that c-Myc has a plethora of functions, including ribosome biosynthesis, metabolism, transcription activation and repression, it is possible that these dominate in an Apc-deficient background (Bommer and Fearon, 2007) . Thus, it could be argued that the genetic rescue that was observed was due to the complete loss of function of c-Myc rather than the loss of b-catenin-dependent induction of c-Myc. Given the importance of the Apc gene loss in colorectal cancer and our data suggesting c-Myc as the major modifier, in this study we have investigated whether modifying (rather than removing) the levels of Myc after APC loss strongly impacts on the phenotypes of APC loss and tumourigenesis. To do this, we have investigated the phenotype of APC-deficient intestinal epithelium, which was also heterozygous for Myc inactivation.
First, we intercrossed mice carrying the cytochrome P450-inducible AhCre þ transgene to mice carrying loxpinducible knockout Apc 580S (Shibata et al., 1997) (Figures 1b and c) 
Note that the enlarged crypts in Apc-deficient mice (c) are reduced in the Myc heterozygote crypts (d). The black vertical bars indicate the size of the crypt compartment. (e-g) Immunohistochemistry (IHC) for BrdU (Sansom et al., 2004) 
and Apc-deficient Myc heterozygote (AhCre þ Apc fl/fl Myc fl/ þ ) (g) intestines, 4 days after cre induction and 2 h after BrdU injection. Note that Apc-deficient Myc heterozygote (g) intestines are much smaller than the Apc-deficient intestine (f). BrdU IHC was performed using an anti-BrdU antibody (BD Pharmingen Oxford, UK, cat. no. 347580) at a 1:100 dilution. , labelling occurs in a much smaller zone (consistent with less proliferation), but there is still no movement between 2 and 24 h (red and blue lines) unlike wild-type intestines (see Sansom et al., 2004) . For comparison, graphs from wild-type (AhCre
Here, labelling occurs only in the crypt at 2 h (light blue line), but the cells migrate into the villus at the later time point (orange line). All Experiments were performed under the UK Home Office guidelines. Outbred male mice from 6 to 12 weeks of age were used, which were segregating for the C57BLJ and S129 genomes. Figures 1f, g and i) . In both cases, crypt size and proliferation were reduced to B50% (Figures 1h and i) . Interestingly, not all of the phenotypes of Apc deficiency were modified; for example, failed intestinal enterocyte movement up the crypt-villus axis was still evident in AhCre Myc þ / þ mice (data not shown). This could represent the moderately increased levels of Myc, which are still twofold over levels in Apc wild-type intestine, arguing that the highest levels of Myc are required to drive proliferation and probably apoptosis after Apc loss, although lower levels (yet still increased compared with wild type) perturb migration within the intestinal crypt. These data are consistent with a recent study showing that the precise levels of Myc overexpression in vivo govern the biological output . In this study, a clear twofold difference in Myc levels could drive differences in proliferation in a number of tissues.
To assess mechanistically how Myc haploinsufficiency was affecting the phenotypes of Apc loss, we first stained for levels of nuclear b-catenin. As expected with c-Myc being a transcriptional target of b-catenin, we found nuclear b-catenin in the crypt cells of both AhCre (Figures 2a-c) . This argues that Myc heterozygosity did not have an effect upstream of b-catenin signalling. Given that the major function of c-Myc is as a transcriptional activator and repressor, we next investigated the expression of a number of Wnt target genes Myc levels are crucial after Apc loss D Athineos and OJ Sansom that are deregulated after APC loss (Sansom et al., 2004 (Sansom et al., , 2007 . Importantly, we have shown that the expression of these targets are returned to wild-type levels in double knockout Apc and Myc intestines (Sansom et al., 2007) . Figure 2d shows intestines (indicated with an asterisk in the table). Once again, the reduction was not as dramatic as complete Myc deletion, as target gene expression was still increased in 9 out of 12 genes compared with wild-type intestines. These data highlight that the reduced levels of c-Myc activation after APC loss leads to lower activation of target genes deregulated after APC loss and a reduced phenotype in the intestine in vivo. Of the genes downregulated, Ascl2 was reduced back to wild-type levels. Recent studies have shown that Ascl2 is a Wnt target gene and overexpression of this alone is sufficient to cause increased intestinal enterocyte proliferation and crypt size (Jubb et al., 2006; van der Flier et al., 2009) . This reduction of Ascl2, in conjunction with reduction of Cyclin D2, provides a ready mechanism for reduced crypt proliferation and size in c-Myc heterozygotes.
Finally, we wanted to assess the downstream consequences of Myc heterozygosity to intestinal tumourigenesis after Apc loss. We have previously shown that AhCre þ Apc fl/ þ mice develop intestinal adenomas associated with the loss of the remaining Apc allele and a clear nuclear accumulation of b-catenin within the adenomas (Sansom et al., 2006) . To assess the consequences of Myc heterozygosity on this phenotype, we generated cohorts of experimental
The mice were injected with 3 Â 80 mg/kg b-naphthoflavone in a single day to induce maximal cre-mediated recombination within the intestinal epithelium (Sansom et al., 2006) and aged until they developed symptoms of intestinal disease. These included paling of feet because of anaemia caused by intestinal polyposis, hunching and weight loss. When mice showed these symptoms, they were killed and the intestines removed and intestinal tumour size and number scored. Myc heterozygosity strongly suppressed intestinal tumourigenesis in these mice (Figure 3a) with
mice having a median age of 265 days at death and (Figure 3g ). Given that AhCre deletes specifically within the intestinal epithelium, it suggests that the mechanism that underlies delayed tumour growth is inefficient target gene activation. Interestingly, a previous study has suggested that Myc may affect tumour growth within the intestinal epithelium by allowing tumour angiogenesis (Yekkala and Baudino, 2007) . Therefore, both studies underline the importance of c-Myc levels for intestinal tumour progression and there may be multiple key tumour-promoting mechanisms that c-Myc impinges on. This link between Myc and angiogenesis had been observed previously in pancreatic islet tumour growth driven by c-Myc overexpression and appears dependent on changes in c-Myc levels within the epithelial cells (Shchors et al., 2006) .
Taken together, our results here show that the level of Myc upregulation is absolutely critical for transformation after Apc loss in vivo and thus suggests that levels of c-Myc will be crucial for colorectal cancer in humans. Two recent studies highlight that this may be the case (Pomerantz et al., 2009; Tuupanen et al., 2009) . These studies identified within humans that a polymorphism in 8q24, rs6983267, which is associated with increased colorectal cancer risk, is an enhancer region within the TCF7L2 (TCF4) gene, with the tumour-prone allele more strongly activating Wnt signalling. Both studies showed that c-Myc could bind to this promoter and one suggested a direct interaction with c-Myc (Pomerantz et al., 2009) . These studies also highlight the cooperation between Wnt and c-Myc in colorectal cancer. It should be noted that an activation of c-Myc alone is not sufficient to drive the intestinal phenotypes equivalent to APC loss, instead in APC-deficient cells c-Myc is essential (Sansom et al., 2007; Murphy et al., 2008) . Indeed, a recent study (Finch et al., 2009) shows that very high expression of c-Myc could only recapitulate a subset of the phenotypes of Apc loss and target gene activation. Therefore, this shows the requirement for co-operation between nuclear b-catenin and c-Myc in driving the phenotypes after Apc loss. In this study, we show that there is an optimal level of c-Myc activation after Apc loss, so reducing the deregulation of c-Myc by just twofold is sufficient to suppress tumour growth, invasion and modify target gene activation.
There has been much debate over whether c-Myc is a therapeutic target for colorectal cancer and the difficulties regarding targeting c-Myc using small molecules (Soucek et al., 2008; Wilkins and Sansom, 2008) . Our study here suggests that reduction of c-Myc (as well as complete ablation) may be a rationale for chemoprevention of colorectal cancer. This is consistent with a recent study in the mouse which displayed that haploinsufficiency for MYB caused reduced c-Myc levels and slowed intestinal tumourigenesis in the Apc Min/ þ mouse (Ciznadija et al., 2009). Thus, Myc or proteins that regulate c-Myc expression levels may be potential therapeutical targets in the future.
